I Want To...
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
School of Medicine
I Want to...
Emily Ann Kendall, M.D.
Assistant Professor of Medicine
Languages: English, German, Spanish
Research Interests: Infectious disease dynamics; tuberculosis; drug resistance; treatment and regimen development; mechanistic modeling
Contact for Research Inquiries
725 N. Wolfe St. Suite 211
Baltimore, MD 21205 map
Dr. Emily Kendall is an Assistant Professor of Medicine in the Infectious Diseases division at the Johns Hopkins University School of Medicine. Her research focuses on infectious diseases dynamics and antibiotic resistance.
Her current work focuses on understanding tuberculosis transmission, treatment outcomes, and regimen development. She uses mathematical models and computational approaches to guide optimal use of drug regimens and other tools for more effectively combating tuberculosis on the level of individual patients and large-scale epidemics.
Dr. Kendall received her B.A. from Harvard University and her M.D. from the Vanderbilt University School of Medicine. She completed her residency at Massachusetts General Hospital and a fellowship in infectious diseases at Johns Hopkins.
- Assistant Professor of Medicine
Centers & Institutes
- MD, Vanderbilt University School of Medicine (2010)
- Massachusetts General Hospital / Internal Medicine (2013)
- Johns Hopkins University School of Medicine / Infectious Diseases (2016)
- American Board of Internal Medicine / Infectious Disease (2015)
- American Board of Internal Medicine / Internal Medicine (2013)
Research & Publications
Lab Website: Emily Kendall Lab
Kendall EA, Fojo AT, Dowdy DW. Expected effects of adopting a 9 month regimen for multidrug-resistant tuberculosis: a population modelling analysis. Lancet Respir Med. 2017 Mar;5(3):191-199.
Kendall EA, Shrestha S, Cohen T, Nuermberger E, Dooley KE, Gonzalez-Angulo L, Churchyard GJ, Nahid P, Rich ML, Bansbach C, Forissier T, Lienhardt C, Dowdy DW. Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model. PLoS Med. 2017 Jan 3;14(1):e1002202.
Kendall EA, Azman AS, Cobelens FG, Dowdy DW. MDR-TB treatment as prevention: The projected population-level impact of expanded treatment for multidrug-resistant tuberculosis. PLoS One. 2017 Mar 8;12(3):e0172748
Kendall EA, Cohen T, Mitnick CD, Dowdy DW. Second line drug susceptibility testing to inform the treatment of rifampin-resistant tuberculosis: a quantitative perspective. Int J Infect Dis. 2017 Mar;56:185-189.
Kendall EA, Fofana MO, Dowdy DW. "Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis." Lancet Respir Med. 2015 Dec;3(12):963-72. doi: 10.1016/S2213-2600(15)00458-0. Epub 2015 Nov 18.